Prostate cancer screening.
Universal screening for prostate cancer (Pca) using prostate-specific antigen-based testing is not recommended, as the potential harms of screening (overdiagnosis and overtreatment) outweigh potential benefits. The case for Pca screening requires a paradigm shift, which emphasizes the risks of screening over the risks of undetected cancer. Physicians are encouraged to use shared decision making with patients who express an interest in Pca screening, taking into account both the patient's screening preferences and individual risk profile. New models of care informed by the Patient Protection and Affordable Care Act are intended to assist clinicians in providing recommended preventive services.
Department of Community and Family Medicine, Duke Family Medicine Center, Duke University, 2100 Erwin Drive, Durham, NC 27710, USA. Electronic address: john.ragsdale@duke.edu.
John W
JW
Ragsdale
Department of Community and Family Medicine, Duke Family Medicine Center, Duke University, 2100 Erwin Drive, Durham, NC 27710, USA.
Brian
B
Halstater
Department of Community and Family Medicine, Duke Family Medicine Center, Duke University, 2100 Erwin Drive, Durham, NC 27710, USA.
Viviana
V
Martinez-Bianchi
D003661:Decision Support Techniques; D055088:Early Detection of Cancer / Q000379:methods*; D006801:Humans; D008297:Male; D010358:Patient Participation; D017410:Practice Guidelines as Topic; D011320:Primary Health Care / Q000458:organization & administration*; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology; D012307:Risk Factors
D017430:Prostate-Specific Antigen
DRE; Digital rectal examination; PSA; Prostate cancer; Prostate-specific antigen; Screening